vs 9,698 other HR bills in the 117th — cohort avg 63d
Summary
Accelerating Access to Critical Therapies for ALS Act This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions. The Department of Health and Human Services (HHS) shall award grants to eligible entities for scientific research utilizing data from expanded access to investigational ALS treatments for individuals who are not otherwise eligible for clinical trials. The Food and Drug Administration (FDA) shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other rare neurodegenerative diseases. HHS shall also establish the Public-Private Partnership for Neurodegenerative Diseases between the National Institutes of Health, the FDA, and at least one eligible entity (generally, an institution of higher education or a nonprofit organization). The partnership shall support the development and regulatory review of drugs that address ALS and other rare neurodegenerative diseases. The FDA shall publish on its website a five-year action plan for fostering the development of drugs that improve or extend the lives of people living with rare neurodegenerative diseases. The Government Accountability Office must report to Congress about the grants provided under this bill, including an analysis of the impact of such grants on research and development of treatments for ALS.
Vote Summary
Yes
423
No
3
Present
0
Not Voting
7
Party Breakdown
Democrats:217 Y0 N
Republicans:206 Y3 N
Bipartisan Score: 9493%
Roll Call
Chamber
Question
Result
Date
#415
Lobbying filings that explicitly cite this bill (36)
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
On Motion to Suspend the Rules and Pass, as Amended
Passed
December 8, 2021
Advocated for robust funding for the Newborn Screening programs at the CDC, NIH, and HRSA Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, Centers for Disease Control and Prevention, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions. Advocated for increased funding of the National Center for Advancing Translational Sciences (NCATS) Advocated for the swift funding and implementation of the ACT for ALS Act (S.1813 and H.R.3537). Advocated for increased funding of home and community-based services (HCBS). Advocated for greater funding amounts going towards Department of Education programs focused on educational offerings for those with disabilities. Advocated for additional funding for the Social Security Administration to implement programs for those with disabilities
Client expense: $220,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Cited source text, amounts, lobbyists, and targets
Health care issues affecting individuals with neuromuscular disease including therapy development, newborn screening, screening and diagnosis, adequate insurance coverage, and access to care. Advocated for the passage of the Newborn Screening Saves Lives Reauthorization Act, H.R. 482 / S. 350, to encourage investment in the national newborn screening program in order to detect more neuromuscular conditions early to speed appropriate interventions for patients. Advocated for robust funding of the national newborn screening program. Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, Centers for Disease Control and Prevention, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions. Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions. Advocated for the swift funding and implementation of the ACT for ALS Act (S.1813 and H.R.3537). Advocated for access to healthcare via telemedicine/telehealth throughout and after the COVID-19 public health emergency. Advocated for increased funding of home and community-based services (HCBS). Supported the passage of the e Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act (H.R. 5030/S. 2706) Advocated for reforms to the FDA Accelerated Approval program as part of the end-of-year omnibus package. Advocated for the creation of an FDA regulatory pathway for diagnostics, including lab-developed tests and invitro diagnostics. Supported greater appropriations for Consumer Assistance Programs Advocated for the passage of the RARE Act (S. 4185) as part of the end-of-year omnibus package. Supported passage of the Ending the Diagnostic Odyssey Act Advocated for the passage of the Accelerating Kids Access to Care Act Advocated for certain provisions within the Cures 2.0 Legislation (H.R.6000) Support the passage of the Precision Medicine for Children Act Advocated for the passage of the HCBS Access Act Supported the passage of the Stop the Wait Act (S. 3575 / H.R. 6583) Advocated for the Access to Genetic Counselors Act Provided recommendations to the Department of Health and Human Services on the implementation of section 1557 of the Affordable Care Act. Applauded the Department of Health and Human Services in their closing of the family glitch within the Affordable Care Act. Advocated to the Centers for Medicare and Medicaid Services on Medicaid access and the COVID-19 public health emergency Called for passage of the Preserving Patient Access to Home Infusion Act (S. 2652/H.R. 5067) Provided comments to CMS on ensuring equity in accessing health care. Provided comments to the Department of Health and Human Services on how best to streamline eligibility and enrollment within the Medicaid and CHIP programs. Called for recipients of the Deferred Action for Childhood Arrivals program to access Federal health programs and offerings. Provided comments to the CMS on the implementation of the No Surprises Act. Called for greater funding of the National Center for Advancing Translational Sciences (NCATS) Called for the passage of the Medicare Orthotic & Prosthetic Patient-Centered Care Act Provided comments to CMS on National Directory of Healthcare Providers and Services
Client expense: $220,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), Natl Council on Disability, Natl Institutes of Health (NIH), SENATE, Treasury, Dept of
Cited source text, amounts, lobbyists, and targets
Health care issues affecting individuals with neuromuscular disease including therapy development, newborn screening, screening and diagnosis, adequate insurance coverage, and access to care. Advocated for the passage of the Newborn Screening Saves Lives Reauthorization Act, H.R. 482 / S. 350, to encourage investment in the national newborn screening program in order to detect more neuromuscular conditions early to speed appropriate interventions for patients. Advocated for robust funding of the national newborn screening program. Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, Centers for Disease Control and Prevention, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions. Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions. Advocated for the swift funding and implementation of the ACT for ALS Act (S.1813 and H.R.3537). Advocated for access to healthcare via telemedicine/telehealth throughout and after the COVID-19 public health emergency. Advocated for closure of the Medicaid coverage gap and the permanence of the Advanced Premium Tax Credits as part of the Build Back Better Act. Advocated for a robust paid medical leave program. Advocated for increased funding of home and community-based services (HCBS). Supported the passage of the e Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act (H.R. 5030/S. 2706) Advocated for reforms to the FDA Accelerated Approval program as part of the FDA user fee reauthorizations Advocated for the creation of an FDA regulatory pathway for diagnostics, including lab-developed tests and invitro diagnostics. Supported greater appropriations for Consumer Assistance Programs Advocated for the passage of the RARE Act (S. 4185) as part of the Senate FDA User Fee process. Commented on fixing the ACA Family Glitch to the Treasury Department Supported reforms to the HCPCS coding system. Supported passage of the Ending the Diagnostic Odyssey Act Advocated for the passage of the Accelerating Kids Access to Care Act Advocated for certain provisions within the Cures 2.0 Legislation (H.R.6000) Support the passage of the Precision Medicine for Children Act Advocated for the passage of the HCBS Access Act Supported the passage of the Stop the Wait Act (S. 3575 / H.R. 6583) Provided comments to Congress on portions of the Inflation Reduction Act, including the Medicare out-of-pocket cap and smoothing mechanisms. Joined coalition comments on the CY 2023 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment Policies Proposed Rule. Provided policy suggestions to CMS on the annual Notice of Benefit and Payment Parameters. Advocated for greater coverage of seat elevation systems and standing wheelchairs within the Medicare program. Advocated for the Access to Genetic Counselors Act
Client expense: $200,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), Natl Council on Disability, Natl Institutes of Health (NIH), SENATE, Treasury, Dept of
Cited source text, amounts, lobbyists, and targets
Advocated for robust funding for the Newborn Screening programs at the CDC, NIH, and HRSA Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, Centers for Disease Control and Prevention, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions. Advocated for increased funding of the National Center for Advancing Translational Sciences (NCATS) Advocated for the swift funding and implementation of the ACT for ALS Act (S.1813 and H.R.3537). Advocated for increased funding of home and community-based services (HCBS).
Client expense: $200,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Cited source text, amounts, lobbyists, and targets
Advocated for robust funding for the Newborn Screening programs at the CDC, NIH, and HRSA Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, Centers for Disease Control and Prevention, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions. Advocated for increased funding of the National Center for Advancing Translational Sciences (NCATS) Advocated for the swift funding and implementation of the ACT for ALS Act (S.1813 and H.R.3537). Advocated for increased funding of home and community-based services (HCBS). Asked for greater appropriations to assist schools with providing services to individuals with disabilities. Supported greater appropriations for Consumer Assistance Programs
Client expense: $200,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Cited source text, amounts, lobbyists, and targets
Health care issues affecting individuals with neuromuscular disease including therapy development, newborn screening, screening and diagnosis, adequate insurance coverage, and access to care. Advocated for the passage of the Newborn Screening Saves Lives Reauthorization Act, H.R. 482 / S. 350, to encourage investment in the national newborn screening program in order to detect more neuromuscular conditions early to speed appropriate interventions for patients. Advocated for robust funding of the national newborn screening program. Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, Centers for Disease Control and Prevention, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions. Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions. Advocated for the swift funding and implementation of the ACT for ALS Act (S.1813 and H.R.3537). Advocated for access to healthcare via telemedicine/telehealth throughout and after the COVID-19 public health emergency. Advocated for closure of the Medicaid coverage gap and the permanence of the Advanced Premium Tax Credits as part of the Build Back Better Act. Advocated for a robust paid medical leave program. Advocated for increased funding of home and community-based services (HCBS). Supported the passage of the e Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act (H.R. 5030/S. 2706) Advocated for reforms to the FDA Accelerated Approval program as part of the FDA user fee reauthorizations Advocated for the creation of an FDA regulatory pathway for diagnostics, including lab-developed tests and invitro diagnostics. Drafted recommendations to the Centers for Medicare and Medicaid Services on strengthening the Medicaid program. Supported the Administrations efforts to withdraw the previous Administrations Public Charge rule. Submitted recommendations to the Department of Health and Human Services on the implementation of section 504 of the Rehabilitation Act. Supported greater appropriations for Consumer Assistance Programs Advocated to the Architectural and Transportation Barriers Compliance Board (ATBCB) for amended Standards for Accessible Medical Diagnostic Equipment. Advocated for the passage of the RARE Act (S. 4185) as part of the Senate FDA User Fee process. Commented on fixing the ACA Family Glitch to the Treasury Department Supported reforms to the HCPCS coding system. Supported passage of the Ending the Diagnostic Odyssey Act Advocated for the passage of the Accelerating Kids Access to Care Act Advocated for certain provisions within the Cures 2.0 Legislation (H.R.6000) Support the passage of the Precision Medicine for Children Act Advocated for the passage of the HCBS Access Act Supported the passage of the Stop the Wait Act (S. 3575 / H.R. 6583)
Cited source text, amounts, lobbyists, and targets
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $10,000
Cited source text, amounts, lobbyists, and targets
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $20,000
Cited source text, amounts, lobbyists, and targets
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $100,000
Cited source text, amounts, lobbyists, and targets
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $20,000
Cited source text, amounts, lobbyists, and targets
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $40,000
Cited source text, amounts, lobbyists, and targets
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $20,000
Cited source text, amounts, lobbyists, and targets
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $20,000
Cited source text, amounts, lobbyists, and targets
-Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act (H.R. 708/ S. 168) temporarily authorizes the interstate provision of in-person and telehealth services. This authorization applies during, and for at least 180 days after, the COVID-19 (i.e., coronavirus disease 2019) emergency. Specifically, subject to scope of practice and other requirements, a health care professional may provide health services in any U.S. jurisdiction based on that individual's authorization to practice in any one state or territory. The bill also provides certain related powers to health care professional regulatory bodies, such as medical boards. Specifically, a regulatory body may investigate and take disciplinary actions against a professional who provides services pursuant to this bill to a patient in that body's jurisdiction. -The Promising Pathway Act (S. 1644) would establish a new time-limited "provisional approval" path at the FDA for drug sponsors to market drugs that show promise while additional testing takes place and before full FDA approval is achieved. -Accelerating Access to Critical Therapies (ACT) for ALS Act (H.R. 3537/ S. 1813) would create 1) a new framework for delivering experimental therapies to people with rare neurodegenerative diseases such as ALS; 2) create a new research grant program at the FDA to such diseases, and; 3) create a new Public-Private Partnership at the Department of Health and Human Services to coordinate federal efforts on developing and approving treatments for such diseases. -Promising Pathway Act (H.R. 3761/S. 1644) would create a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS. CURES 2.0 Act (H.R. 6000) -- Provisions related to drug development, research, and access to emerging therapies for Americans with ALS and other rare diseases through the creation of ARPA-H and other mechanisms. - Build Back Better Act (H.R. 5376) -- Provisions related to providing up to 12 weeks of paid family and medical leave; extending Medicare telehealth flexibilities beyond the COVID-19 public health emergency; and the establishment Advanced Research Projects Agency for Health (ARPA-H). - Telehealth Modernization Act (H.R. 1332/S. 368) -- Provisions related to the modification of requirements relating to coverage of telehealth services under Medicare bill, including certain flexibilities that were initially authorized during the public health emergency relating to COVID-19. - ACT for ALS (P.L. 117-70) - Conversations surrounding implementation of PL 117-79, the Accessing Critical Therapies for ALS Act.
Cited source text, amounts, lobbyists, and targets
Health care issues affecting individuals with neuromuscular disease including therapy development, newborn screening, screening and diagnosis, adequate insurance coverage, and access to care. Advocated for the passage of the Newborn Screening Saves Lives Reauthorization Act, H.R. 482 / S. 350, to encourage investment in the national newborn screening program in order to detect more neuromuscular conditions early to speed appropriate interventions for patients. Advocated for robust funding of the national newborn screening program. Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, Centers for Disease Control and Prevention, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions. Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions. Advocated for the swift funding and implementation of the ACT for ALS Act (S.1813 and H.R.3537). Advocated for access to healthcare via telemedicine/telehealth throughout and after the COVID-19 public health emergency. Advocated for the passage of the Air Carrier Access Amendments Act (S.642 and H.R.1696) Advocated for closure of the Medicaid coverage gap and the permanence of the Advanced Premium Tax Credits as part of the Build Back Better Act. Advocated for a robust paid medical leave program. Advocated for the Transformation to Competitive Integrated Employment Act (H.R.2373 and S.3238) Advocated for increased funding of home and community-based services (HCBS). Advocated for passage of the Disability Employment Incentive Act. Supported the passage of the e Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act (H.R. 5030/S. 2706) Advocated for the permanent adoption of the changes to the Earned Income Tax Credit (EITC) and the Child Tax Credit (CTC). Provided feedback and comments to the Senate's PREVENT Act.
Cited source text, amounts, lobbyists, and targets
Health care issues affecting individuals with neuromuscular disease including therapy development, newborn screening, screening and diagnosis, adequate insurance coverage, and access to care.
Advocated for the passage of the Newborn Screening Saves Lives Reauthorization Act, H.R. 482 / S. 350, to encourage investment in the national newborn screening program in order to detect more neuromuscular conditions early to speed appropriate interventions for patients.
Advocated for robust funding of the national newborn screening program.
Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, Centers for Disease Control and Prevention, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions.
Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions.
Advocated for the passage of the ACT for ALS Act (S.1813 and H.R.3537).
Advocated for access to healthcare via telemedicine/telehealth throughout and after the COVID-19 public health emergency.
Advocated for the passage of the Air Carrier Access Amendments Act (S.642 and H.R.1696)
Advocated for the protection of the Orphan Drug Tax Credit as part of the Build Back Better Act.
Advocated for closure of the Medicaid coverage gap and the permanence of the Advanced Premium Tax Credits as part of the Build Back Better Act.
Advocated for a robust paid medical leave program as part of the Build Back Better Act.
Supported the Competitive Integrated Employment Grants program as part of the Build Back Better Act.
Advocated for increased funding of home and community-based services (HCBS) as part of the Build Back Better Act
Advocated for passage of the Disability Employment Incentive Act.
Supported the passage of the e Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act (H.R. 5030/S. 2706)
Cited source text, amounts, lobbyists, and targets
-Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act (H.R. 708/ S. 168) temporarily authorizes the interstate provision of in-person and telehealth services. This authorization applies during, and for at least 180 days after, the COVID-19 (i.e., coronavirus disease 2019) emergency. Specifically, subject to scope of practice and other requirements, a health care professional may provide health services in any U.S. jurisdiction based on that individual's authorization to practice in any one state or territory. The bill also provides certain related powers to health care professional regulatory bodies, such as medical boards. Specifically, a regulatory body may investigate and take disciplinary actions against a professional who provides services pursuant to this bill to a patient in that body's jurisdiction.
-The Promising Pathway Act (S. 1644) would establish a new time-limited "provisional approval" path at the FDA for drug sponsors to market drugs that show promise while additional testing takes place and before full FDA approval is achieved.
-Accelerating Access to Critical Therapies (ACT) for ALS Act (H.R. 3537/ S. 1813) would create 1) a new framework for delivering experimental therapies to people with rare neurodegenerative diseases such as ALS; 2) create a new research grant program at the FDA to such diseases, and; 3) create a new Public-Private Partnership at the Department of Health and Human Services to coordinate federal efforts on developing and approving treatments for such diseases.
-Promising Pathway Act (H.R. 3761/S. 1644) would create a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS.
CURES 2.0 Act (H.R. 6000) -- Provisions related to drug development, research, and access to emerging therapies for Americans with ALS and other rare diseases through the creation of ARPA-H and other mechanisms.
Build Back Better Act (H.R. 5376) -- Provisions related to providing up to 12 weeks of paid family and medical leave; extending Medicare telehealth flexibilities beyond the COVID-19 public health emergency; and the establishment Advanced Research Projects Agency for Health (ARPA-H).
Telehealth Modernization Act (H.R. 1332/S. 368) -- Provisions related to the modification of requirements relating to coverage of telehealth services under Medicare bill, including certain flexibilities that were initially authorized during the public health emergency relating to COVID-19.
Cited source text, amounts, lobbyists, and targets
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: $40,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $10,000
Cited source text, amounts, lobbyists, and targets
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $100,000
Cited source text, amounts, lobbyists, and targets
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $20,000
Cited source text, amounts, lobbyists, and targets
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $40,000
Cited source text, amounts, lobbyists, and targets
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $20,000
Cited source text, amounts, lobbyists, and targets
Health care issues affecting individuals with neuromuscular disease including therapy development, newborn screening, screening and diagnosis, adequate insurance coverage, and access to care.
Advocated for the passage of the Newborn Screening Saves Lives Reauthorization Act, H.R. 482 / S. 350, to encourage investment in the national newborn screening program in order to detect more neuromuscular conditions early to speed appropriate interventions for patients.
Advocated for robust funding of the national newborn screening program.
Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, Centers for Disease Control and Prevention, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions.
Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions.
Advocated for the passage of the ACT for ALS Act (S.1813 and H.R.3537).
Advocated for access to healthcare via telemedicine/telehealth throughout and after the COVID-19 public health emergency.
Advocated for the passage of the Air Carrier Access Amendments Act (S.642 and H.R.1696)
Advocated for the protection of the Orphan Drug Tax Credit as part of the Build Back Better Act.
Advocated for closure of the Medicaid coverage gap and the permanence of the Advanced Premium Tax Credits as part of the Build Back Better Act.
Advocated for a robust paid medical leave program as part of the Build Back Better Act.
Supported the Competitive Integrated Employment Grants program as part of the Build Back Better Act.
Advocated for passage of the Disability Employment Incentive Act.
Client expense: $100,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
-Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act (H.R. 708/ S. 168) temporarily authorizes the interstate provision of in-person and telehealth services. This authorization applies during, and for at least 180 days after, the COVID-19 (i.e., coronavirus disease 2019) emergency. Specifically, subject to scope of practice and other requirements, a health care professional may provide health services in any U.S. jurisdiction based on that individual's authorization to practice in any one state or territory. The bill also provides certain related powers to health care professional regulatory bodies, such as medical boards. Specifically, a regulatory body may investigate and take disciplinary actions against a professional who provides services pursuant to this bill to a patient in that body's jurisdiction.
-The Promising Pathway Act (S. 1644) would establish a new time-limited "provisional approval" path at the FDA for drug sponsors to market drugs that show promise while additional testing takes place and before full FDA approval is achieved.
-Accelerating Access to Critical Therapies (ACT) for ALS Act (H.R. 3537/ S. 1813) would create 1) a new framework for delivering experimental therapies to people with rare neurodegenerative diseases such as ALS; 2) create a new research grant program at the FDA to such diseases, and; 3) create a new Public-Private Partnership at the Department of Health and Human Services to coordinate federal efforts on developing and approving treatments for such diseases.
-Promising Pathway Act (H.R. 3761/S. 1644) would create a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS.
Client expense: $25,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
Health care issues affecting individuals with neuromuscular disease including therapy development, newborn screening, screening and diagnosis, adequate insurance coverage, and access to care.
Advocated for the passage of the Newborn Screening Saves Lives Reauthorization Act, H.R. 482 / S. 350, to encourage investment in the national newborn screening program in order to detect more neuromuscular conditions early to speed appropriate interventions for patients.
Advocated for robust funding of the national newborn screening program.
Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, Centers for Disease Control and Prevention, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions.
Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions.
Advocated for the passage of the ACT for ALS Act (S.1813 and H.R.3537).
Advocated for access to healthcare via telemedicine/telehealth throughout and after the COVID-19 public health emergency.
Advocated for equitable access to the COVID-19 vaccines for the neuromuscular disease community.
Advocated for the passage of the Air Carrier Access Amendments Act (S.642 and H.R.1696)
Advocated for additional funding of the Consumer Assistance Programs (CAPs) available to individuals seeking health insurance.
Client expense: $100,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
-Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act (H.R. 708/ S. 168) temporarily authorizes the interstate provision of in-person and telehealth services. This authorization applies during, and for at least 180 days after, the COVID-19 (i.e., coronavirus disease 2019) emergency. Specifically, subject to scope of practice and other requirements, a health care professional may provide health services in any U.S. jurisdiction based on that individual's authorization to practice in any one state or territory. The bill also provides certain related powers to health care professional regulatory bodies, such as medical boards. Specifically, a regulatory body may investigate and take disciplinary actions against a professional who provides services pursuant to this bill to a patient in that body's jurisdiction.
-The Promising Pathway Act (S. 1644) would establish a new time-limited "provisional approval" path at the FDA for drug sponsors to market drugs that show promise while additional testing takes place and before full FDA approval is achieved.
-Accelerating Access to Critical Therapies (ACT) for ALS Act (H.R. 3537/ S. 1813) would create 1) a new framework for delivering experimental therapies to people with rare neurodegenerative diseases such as ALS; 2) create a new research grant program at the FDA to such diseases, and; 3) create a new Public-Private Partnership at the Department of Health and Human Services to coordinate federal efforts on developing and approving treatments for such diseases.
-Promising Pathway Act (H.R. 3761/S. 1644) would create a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS.
Client expense: $25,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
-Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act (H.R. 708/ S. 168) temporarily authorizes the interstate provision of in-person and telehealth services. This authorization applies during, and for at least 180 days after, the COVID-19 (i.e., coronavirus disease 2019) emergency. Specifically, subject to scope of practice and other requirements, a health care professional may provide health services in any U.S. jurisdiction based on that individual's authorization to practice in any one state or territory. The bill also provides certain related powers to health care professional regulatory bodies, such as medical boards. Specifically, a regulatory body may investigate and take disciplinary actions against a professional who provides services pursuant to this bill to a patient in that body's jurisdiction.
-The Promising Pathway Act (S. 1644) would establish a new time-limited "provisional approval" path at the FDA for drug sponsors to market drugs that show promise while additional testing takes place and before full FDA approval is achieved.
-Accelerating Access to Critical Therapies (ACT) for ALS Act (H.R. 3537/ S. 1813) would create 1) a new framework for delivering experimental therapies to people with rare neurodegenerative diseases such as ALS; 2) create a new research grant program at the FDA to such diseases, and; 3) create a new Public-Private Partnership at the Department of Health and Human Services to coordinate federal efforts on developing and approving treatments for such diseases.
-Promising Pathway Act (H.R. 3761/S. 1644) would create a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS.
Client expense: $25,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
-The Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act (H.R. 708/ S. 168) temporarily authorizes the interstate provision of in-person and telehealth services. This authorization applies during, and for at least 180 days after, the COVID-19 (i.e., coronavirus disease 2019) emergency. Specifically, subject to scope of practice and other requirements, a health care professional may provide health services in any U.S. jurisdiction based on that individual's authorization to practice in any one state or territory. The bill also provides certain related powers to health care professional regulatory bodies, such as medical boards. Specifically, a regulatory body may investigate and take disciplinary actions against a professional who provides services pursuant to this bill to a patient in that body's jurisdiction.
-The Promising Pathway Act (S. 1644) would establish a new time-limited "provisional approval" path at the FDA for drug sponsors to market drugs that show promise while additional testing takes place and before full FDA approval is achieved.
-The Accelerating Access to Critical Therapies (ACT) for ALS Act (H.R. 3537/ S. 1813) would create 1) a new framework for delivering experimental therapies to people with rare neurodegenerative diseases such as ALS; 2) create a new research grant program at the FDA to such diseases, and; 3) create a new Public-Private Partnership at the Department of Health and Human Services to coordinate federal efforts on developing and approving treatments for such diseases.
Client expense: $33,719 · Firm income: Not reported
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 423 - 3 (Roll no. 415). (text: CR H7509-7511)
House
December 8, 2021
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 423 - 3 (Roll no. 415).(text: CR H7509-7511)
House
December 8, 2021
Considered as unfinished business. (consideration: CR H7535-7536)
December 8, 2021
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
December 8, 2021
DEBATE - The House proceeded with forty minutes of debate on H.R. 3537.
December 8, 2021
Considered under suspension of the rules. (consideration: CR H7509-7514)
December 8, 2021
Mr. Pallone moved to suspend the rules and pass the bill, as amended.
December 8, 2021
Placed on the Union Calendar, Calendar No. 148.
December 8, 2021
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-207.
Congress.gov source codes: 5000, H12200
November 17, 2021
Ordered to be Reported (Amended) by Voice Vote.
November 17, 2021
Committee Consideration and Mark-up Session Held.
November 4, 2021
Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
November 4, 2021
Subcommittee Consideration and Mark-up Session Held.
May 26, 2021
Referred to the Subcommittee on Health.
May 25, 2021
Referred to the House Committee on Energy and Commerce.
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), Natl Council on Disability, Natl Institutes of Health (NIH), SENATE, Treasury, Dept of
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), Natl Council on Disability, Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE, Treasury, Dept of
Client expense: $100,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Federal Aviation Administration (FAA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE, Transportation, Dept of (DOT), Treasury, Dept of
Client expense: $25,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Federal Aviation Administration (FAA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE, Transportation, Dept of (DOT), Treasury, Dept of
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Federal Aviation Administration (FAA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE, Transportation, Dept of (DOT), Treasury, Dept of